{"commentary":{"count":222,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":104,"podcast":65,"youtube":52,"x_video":1},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03937219\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"COSMIC-313","nct_id":"NCT03937219","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cosmic-313-nct03937219. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"COSMIC-313","arms":[{"description":"Cabozantinib + nivolumab + ipilimumab (4 doses) followed by cabozantinib + nivolumab","label":"Experimental Arm","type":"EXPERIMENTAL"},{"description":"Cabozantinib-matched placebo + nivolumab + ipilimumab (4 doses) followed by cabozantinib-matched placebo + nivolumab","label":"Control Arm","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-01-31","type":"ESTIMATED"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":855,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Cabozantinib","type":"DRUG"},{"name":"Nivolumab","type":"BIOLOGICAL"},{"name":"Ipilimumab","type":"BIOLOGICAL"},{"name":"Cabozantinib-matched placebo","type":"DRUG"}],"last_update":"2025-09-10","lead_sponsor":"Exelixis","official_title":"A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination With Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Subjects With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Risk","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2022-01-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Duration of Progression-Free Survival (PFS) by Blinded Independent Radiology Committee (BIRC)","timeFrame":"Up to 32 months"}],"references":[{"citation":"Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851.","pmid":"37163623","type":"DERIVED"},{"citation":"Labriola MK, George DJ. Setting a new standard for long-term survival in metastatic kidney cancer. Cancer. 2022 Jun 1;128(11):2058-2060. doi: 10.1002/cncr.34177. Epub 2022 Apr 5. No abstract available.","pmid":"35383907","type":"DERIVED"},{"citation":"Mar N, Kaakour D, Rezazadeh Kalebasty A. Renal Cell Carcinoma-Lessons in Diversity, Breakthroughs, and Challenges. JCO Oncol Pract. 2022 Mar;18(3):197-199. doi: 10.1200/OP.21.00446. Epub 2021 Sep 22. No abstract available.","pmid":"34550754","type":"DERIVED"},{"citation":"Hofmann F, Hwang EC, Lam TB, Bex A, Yuan Y, Marconi LS, Ljungberg B. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2020 Oct 14;10(10):CD012796. doi: 10.1002/14651858.CD012796.pub2.","pmid":"33058158","type":"DERIVED"}],"start_date":{"date":"2019-06-25","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma","url":"https://clinicaltrials.gov/study/NCT03937219"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cosmic-313-nct03937219"}